Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia

Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia

ABSTRACT Background Real‐world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited. Methods We evaluated outcomes of patients with newly‐diagnosed AML treated with HMA + VEN50 with either posaconazole (n =...

Full description

Saved in:
Bibliographic Details
Main Authors: Kendall Diebold, Devan Parker, Sarah Worth, Manuel Espinoza‐Gutarra, Pankit Vachhani, Kimo Bachiashvili, Sravanti Rangaraju, Razan Mohty, Ravi Bhatia, Omer Jamy
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:eJHaem
Subjects:
acute myeloid leukemia (AML)
posaconazole
Venetoclax 50 mg
voriconazole
Online Access:https://doi.org/10.1002/jha2.70049
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items